Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$6.39 ▼ -0.09
(-1.39%)
MKT CAP: $685.2M • VOL: 964.7K
52W L $4 52W H $11
ROARABLE / RQD
E • 31/100
PIOTROSKI
1 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$5
MEDIAN
$7
MEAN
$7
HIGH
$9
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SLDB TAPE
SLDB // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $7.73 | $7.35 | 2025-02-14 | $5.81 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $8.05 | $7.54 | 2025-02-06 | $6.01 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $7.28 | $7.03 | 2025-01-29 | $6.13 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $6.52 | — | 2025-01-17 | $6.26 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $5.62 | $6.07 | 2025-01-09 | $5.69 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $7.60 | $6.65 | 2024-12-18 | $5.56 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $6.20 | $6.45 | 2024-12-04 | $5.94 | -4.3% | 48% | C |